Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adagene Inc.ADAG · Entity 6155 | Director | August 14, 2026 | August 18, 2026 |
| BIOVIE INC.BIVI · Entity 7702 | Director · President & CEO | August 27, 2026 | August 28, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Chief Strategy Officer | May 06, 2013 | May 08, 2013 |
| Spark I Acquisition CorpSPKLU · Entity 6756 | Director | October 05, 2023 | October 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adagene Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary Shares (ADS)SEC Table I · non-derivative | Direct | 2,000 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 2,000 · Balance 2,000 F1: These shares were purchased in multiple transactions at prices $3.75 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased in multiple transactions at prices $3.75 per share.
BIOVIE INC.
Report date August 27, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,117 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Purchase · Acquired 15,210 · Balance 16,117 F1: The price reported in Column 4 is a weighted average price at which shares were purchased in several open market transactions on August 27, 2026, at prices ranging from $2.05 to $2.10, inclusive. The reporting person undertakes to provide BioVie Inc., any stockholder of BioVie Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price at which shares were purchased in several open market transactions on August 27, 2026, at prices ranging from $2.05 to $2.10, inclusive. The reporting person undertakes to provide BioVie Inc., any stockholder of BioVie Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Merck & Co., Inc.
Report date May 06, 2013 · Filed May 08, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.98 · Expires 2023-05-05 | Direct | 64,412 |
Reported balance
After 2013-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-05-06 · Grant · Acquired 64,412 · Balance 64,412 F1: The option vests in three equal annual installments beginning May 6, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three equal annual installments beginning May 6, 2014.
Spark I Acquisition Corp
Report date October 05, 2023 · Filed October 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-10-05 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B ordinary shares are convertible for the Issuer's Class A ordinary shares as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-273176) and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares are convertible for the Issuer's Class A ordinary shares as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-273176) and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 28, 2026 20:57 UTC | BIOVIE INC. BIVI · Entity 7702 | PurchaseCommon Stock | 15,210 | $2.08 | $31,636.80 |
DisclosureSEC source: 0001520138-26-000378 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,117 F1 · price: The price reported in Column 4 is a weighted average price at which shares were purchased in several open market transactions on August 27, 2026, at prices ranging from $2.05 to $2.10, inclusive. The reporting person undertakes to provide BioVie Inc., any stockholder of BioVie Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 22:11 UTC | Adagene Inc. ADAG · Entity 6155 | PurchaseAmerican Depositary Shares (ADS) | 2,000 | $3.75 | $7,500.00 |
DisclosureSEC source: 0001104659-26-098426 · tm2623261-4_4seq1.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · shares: These shares were purchased in multiple transactions at prices $3.75 per share. Read SEC document |
| August 13, 2026 Filed Aug 18, 2026 00:30 UTC | Adagene Inc. ADAG · Entity 6155 | GrantNonqualified Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001104659-26-097994 · tm2623261-2_4seq1.xml · derivative · entry 1 DO CUONG V · CIK 0001477037 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Ordinary Shares · 20,000 shares Expires 2036-08-13 F1 · derivative.exercise_date: 20,000 shares of stock option granted on August 13, 2026 under the Adagene Inc. 2021 Performance Incentive Plan, and the option shall vest on April 30, 2027 or the date of the next 20-F filing, whichever is earlier. Read SEC document |
| January 05, 2026 Filed Jan 9, 2026 22:02 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 665,300 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001520138-26-000021 · ownership.xml · derivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 665,300 Underlying: Common Stock · 665,300 shares Expires 2036-01-05 F1 · derivative.exercise_date: 55% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| August 07, 2025 Filed Aug 13, 2025 20:05 UTC | BIOVIE INC. BIVI · Entity 7702 | PurchaseWarrants (right to buy) · Derivative | 5,000 | Not disclosed Strike: $2.50 | Not disclosed |
DisclosureSEC source: 0001520138-25-000251 · ownership.xml · derivative · entry 2 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 5,050 Underlying: Common Stock · 5,000 shares Expires 2030-08-11 F1 · price: The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $2.00 in connection with the issuer's public offering that closed on August 11, 2025. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| August 07, 2025 Filed Aug 13, 2025 20:05 UTC | BIOVIE INC. BIVI · Entity 7702 | PurchaseCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520138-25-000251 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 9,992 F1 · price: The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $2.00 in connection with the issuer's public offering that closed on August 11, 2025. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| December 20, 2024 Filed Jan 7, 2025 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 104,502 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001520138-25-000010 · ownership.xml · derivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 104,502 Underlying: Common Stock · 104,502 shares Expires 2034-12-20 F1 · derivative.exercise_date: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 24, 2024 Filed Jul 12, 2024 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 227,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001520138-24-000239 · ownership.xml · derivative · entry 6 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 227,000 Underlying: Common Stock · 227,000 shares Expires 2034-06-24 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on June 24, 2024. F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 24, 2024 Filed Jul 12, 2024 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | Tax withholdingCommon Stock | 42,000 | $0.47 | $19,908.00 |
DisclosureSEC source: 0001520138-24-000239 · ownership.xml · nonDerivative · entry 4 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 551,948 F1 · date: The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 24, 2024 Filed Jul 12, 2024 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 168,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-24-000239 · ownership.xml · nonDerivative · entry 3 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 593,948 F1 · date: The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024. F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:12 UTC | BIOVIE INC. BIVI · Entity 7702 | PurchaseWarrants (right to buy) · Derivative | 5,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001520138-24-000099 · ownership.xml · derivative · entry 2 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 F1 · price: The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $1.00 in connection with the issuer's public offering that closed on March 6, 2024. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:12 UTC | BIOVIE INC. BIVI · Entity 7702 | PurchaseCommon stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520138-24-000099 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 435,854 F1 · price: The reported securities were purchased by the reporting person at a combined purchase price for a share of common stock and accompanying warrant equal to $1.00 in connection with the issuer's public offering that closed on March 6, 2024. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| February 15, 2024 Filed Jul 12, 2024 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | Tax withholdingCommon Stock | 4,953 | $1.18 | $5,844.54 |
DisclosureSEC source: 0001520138-24-000239 · ownership.xml · nonDerivative · entry 2 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 425,948 F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 23:26 UTC | BIOVIE INC. BIVI · Entity 7702 | PurchaseCommon stock | 10,000 | $1.78 | $17,800.00 |
DisclosureSEC source: 0001520138-23-000522 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,759 Read SEC document |
| June 29, 2023 Filed Jul 4, 2023 00:47 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001520138-23-000275 · ownership.xml · derivative · entry 2 DO CUONG V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: The options vest in three equal annual installments beginning on June 29, 2024 (the first anniversary of the grant date). F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 29, 2023 Filed Jul 4, 2023 00:47 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 149,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000275 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 425,854 F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 21, 2023 Filed Jun 26, 2023 20:06 UTC | BIOVIE INC. BIVI · Entity 7702 | Exercise / conversionRestricted stock units · Derivative | 41,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000269 · ownership.xml · derivative · entry 2 DO CUONG V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 83,014 Underlying: Common Stock · 41,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to the Company's 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's Class A common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 21, 2022 and vest ratably over a three-year period on each anniversary of the grant date. F4 · derivative.expiration_date: The restricted stock units were granted on June 21, 2022 and vest ratably over a three-year period on each anniversary of the grant date. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 21, 2023 Filed Jun 26, 2023 20:06 UTC | BIOVIE INC. BIVI · Entity 7702 | Exercise / conversionCommon Stock | 41,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520138-23-000269 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 271,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Granted pursuant to the Company's 2019 Omnibus Equity Incentive Plan. F2 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 22:49 UTC | BIOVIE INC. BIVI · Entity 7702 | Tax withholdingCOMMON STOCK | 4,953 | $6.12 | $30,312.36 |
DisclosureSEC source: 0001520138-23-000112 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · SEE FOOTNOTE Disclosed balance after: 229,895 F2 · kind: Transaction code F - Payment of tax liability by withholding securities incident to the receipt F1 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| February 16, 2023 Filed Jul 12, 2024 22:01 UTC | BIOVIE INC. BIVI · Entity 7702 | Tax withholdingCommon stock | 4,953 | $5.51 | $27,291.03 |
DisclosureSEC source: 0001520138-24-000239 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 430,901 F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| November 23, 2022 Filed Jan 18, 2023 21:20 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCOMMON STOCK | 79,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000051 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · SEE FOOTNOTE Disclosed balance after: 234,848 F1 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 21, 2022 Filed Jul 7, 2022 20:01 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantRestricted Stock Unit · Derivative | 124,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-22-000280 · ownership.xml · derivative · entry 2 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 124,520 Underlying: Common Stock · 124,520 shares Expires not disclosed F1 · security: Granted pursuant to the Company's 2019 Omnibus Equity Incentive Plan. Options granted by Compensation Committee on June 21, 2022. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest ratably over a three-year period on each anniversary of the grant date. F5 · derivative.expiration_date: The restricted stock units vest ratably over a three-year period on each anniversary of the grant date. F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| June 21, 2022 Filed Jul 7, 2022 20:01 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 124,520 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001520138-22-000280 · ownership.xml · derivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 124,520 Underlying: Common Stock · 124,520 shares Expires 2032-06-21 F1 · security: Granted pursuant to the Company's 2019 Omnibus Equity Incentive Plan. Options granted by Compensation Committee on June 21, 2022. F2 · derivative.exercise_date: The options vest over a three-year period on each anniversary of the grant date. F3 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| December 31, 2021 Filed Jan 25, 2022 17:31 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 21,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-22-000029 · ownership.xml · nonDerivative · entry 1 DO CUONG V · CIK 0001477037 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,759 Read SEC document |
| August 20, 2021 Filed Sep 16, 2021 18:38 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 745,000 | $0.00 Strike: $7.74 | $0.00 |
DisclosureSEC source: 0001520138-21-000556 · ownership.xml · derivative · entry 1 Do Cuong V · CIK 0001477037 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 745,000 Underlying: COMMON STOCK · 745,000 shares Expires 2031-08-19 F2 · derivative.exercise_date: This option was 20% vested upon grant, with an additional 16% on each of the first five anniversaries of the grant. F1 · ownership.nature: Securities are held in the name of Do & Rickles Investments LLC. Read SEC document |
| December 18, 2020 Filed Mar 5, 2021 00:02 UTC | BIOVIE INC. bivi · Entity 7702 | Grantoptions · Derivative | 97,500 | $13.91 Strike: $13.91 | $1,356,225.00 |
DisclosureSEC source: 0001477037-21-000002 · primary_doc.xml · derivative · entry 1 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares are held in the name of Do & Rickles Investments LLC Disclosed balance after: 171,366 Underlying: common stock · 97,500 shares Expires 2023-12-18 F1 · security: non-qualified options issued from company 2019 Omnibus Equity Incentive Plan, subject to continuation of service to company F2 · derivative.exercise_date: 25% vest on grant date; remaining 75% vest over 3-year period on 1st, 2nd, 3rd anniversary of grant date Read SEC document |
| January 19, 2020 Filed Oct 22, 2020 00:03 UTC | BIOVIE INC. bivi · Entity 7702 | Grantoptions · Derivative | 800 | $2.80 Strike: $2.80 | $2,240.00 |
DisclosureSEC source: 0001771317-20-000003 · primary_doc.xml · derivative · entry 3 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 73,866 Underlying: common stock · 800 shares Expires 2025-01-19 F3 · balance_after: On 11/21/2019 a reverse stock split was effected; derivative securities are post-split calculations. F4 · ownership.nature: Shares are held in the name of Do & Rickes Investments LLC Read SEC document |
| January 02, 2020 Filed Oct 22, 2020 00:03 UTC | BIOVIE INC. bivi · Entity 7702 | GrantCommon Stock | 1,600 | $3.50 | $5,600.00 |
DisclosureSEC source: 0001771317-20-000003 · primary_doc.xml · nonDerivative · entry 1 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 96,841 F1 · balance_after: On 11/21/2019 a reverse stock split was effected; total shares indicated are post-split. F2 · ownership.nature: Shares are held in the name of Do & Rickles Investments LLC Read SEC document |
| January 19, 2019 Filed Oct 22, 2020 00:03 UTC | BIOVIE INC. bivi · Entity 7702 | Grantoptions · Derivative | 800 | $3.50 Strike: $3.75 | $2,800.00 |
DisclosureSEC source: 0001771317-20-000003 · primary_doc.xml · derivative · entry 2 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 73,066 Underlying: common stock · 800 shares Expires 2024-01-19 F3 · balance_after: On 11/21/2019 a reverse stock split was effected; derivative securities are post-split calculations. F4 · ownership.nature: Shares are held in the name of Do & Rickes Investments LLC Read SEC document |
| January 02, 2019 Filed Feb 5, 2019 20:51 UTC | BIOVIE INC. bivi · Entity 7702 | GrantCommon Stock | 200,000 | $0.04 | $7,000.00 |
DisclosureSEC source: 0001674006-19-000002 · primary_doc.xml · nonDerivative · entry 1 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 2,871,354 F1 · ownership.nature: Shares are held in the name of Do & Rickles Investments LLC Read SEC document |
| July 03, 2018 Filed Nov 1, 2018 19:40 UTC | BIOVIE INC. bivi · Entity 7702 | GrantWarrants · Derivative | 8,666,666 | $0.02 Strike: $0.02 | $155,999.99 |
DisclosureSEC source: 0001477037-18-000004 · primary_doc.xml · derivative · entry 2 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,033,333 Underlying: Common Stock · 8,666,666 shares Expires 2024-07-02 Read SEC document |
| July 03, 2018 Filed Nov 1, 2018 19:40 UTC | BIOVIE INC. bivi · Entity 7702 | GrantPreferred Stock | 86,666 | $1.50 | $129,999.00 |
DisclosureSEC source: 0001477037-18-000004 · primary_doc.xml · nonDerivative · entry 1 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,666 Read SEC document |
| January 19, 2018 Filed Aug 14, 2018 19:39 UTC | BIOVIE INC. bivi · Entity 7702 | Grantoptions · Derivative | 100,000 | $0.10 Strike: $0.10 | $10,000.00 |
DisclosureSEC source: 0001477037-18-000003 · primary_doc.xml · derivative · entry 5 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,667 Underlying: common stock · 100,000 shares Expires 2023-01-19 Read SEC document |
| January 08, 2018 Filed Aug 14, 2018 19:39 UTC | BIOVIE INC. bivi · Entity 7702 | GrantWarrants · Derivative | 166,667 | $0.15 Strike: $0.15 | $25,000.05 |
DisclosureSEC source: 0001477037-18-000003 · primary_doc.xml · derivative · entry 4 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares are held in the name of Do & Rickles Investments LLC Disclosed balance after: 266,667 Underlying: common stock · 166,667 shares Expires 2025-01-07 Read SEC document |
| January 08, 2018 Filed Aug 14, 2018 19:39 UTC | BIOVIE INC. bivi · Entity 7702 | Disposition to issuercommon stock | 166,667 | $0.15 | $25,000.05 |
DisclosureSEC source: 0001477037-18-000003 · primary_doc.xml · nonDerivative · entry 2 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares are held in the name of Do & Rickles Investments LLC Disclosed balance after: 3,038,021 Read SEC document |
| January 02, 2018 Filed Aug 14, 2018 19:39 UTC | BIOVIE INC. bivi · Entity 7702 | Grantcommon stock | 200,000 | $0.15 | $30,000.00 |
DisclosureSEC source: 0001477037-18-000003 · primary_doc.xml · nonDerivative · entry 1 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares are held in the name of Do & Rickles Investments LLC Disclosed balance after: 2,871,354 Read SEC document |
| December 08, 2016 Filed Aug 14, 2018 19:39 UTC | BIOVIE INC. bivi · Entity 7702 | Grantoptions · Derivative | 100,000 | $0.21 Strike: $0.21 | $21,000.00 |
DisclosureSEC source: 0001477037-18-000003 · primary_doc.xml · derivative · entry 3 Do Cuong V · CIK 0001477037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: common stock · 100,000 shares Expires 2021-12-08 Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 64,412 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011738 · doc4.xml · derivative · entry 1 Do Cuong V · CIK 0001477037 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,412 Underlying: Common Stock · 64,412 shares Expires 2023-05-05 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 73,126 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011183 · doc4.xml · derivative · entry 2 Do Cuong V · CIK 0001477037 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,126 Underlying: Common Stock · 73,126 shares Expires 2022-05-01 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 5,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-011183 · doc4.xml · derivative · entry 1 Do Cuong V · CIK 0001477037 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,090 Underlying: Common Stock · 5,090 shares Expires 2015-05-02 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| November 02, 2011 Filed Nov 3, 2011 19:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 212,224 | $0.00 Strike: $34.19 | $0.00 |
DisclosureSEC source: 0001225208-11-024260 · doc4.xml · derivative · entry 2 Do Cuong V · CIK 0001477037 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,224 Underlying: Common Stock · 212,224 shares Expires 2021-11-01 F2 · derivative.exercise_date: The option vests in three equal installments beginning 11/02/12. Read SEC document |
| November 02, 2011 Filed Nov 3, 2011 19:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 36,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-024260 · doc4.xml · derivative · entry 1 Do Cuong V · CIK 0001477037 · EVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,560 Underlying: Common Stock · 36,560 shares Expires 2014-11-02 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.